Literature DB >> 31811830

R5, a neutralizing antibody to Robo1, suppresses breast cancer growth and metastasis by inhibiting angiogenesis via down-regulating filamin A.

Qianming Li1, Jinghua Cao1, Yajun He1, Xiaohua Liu1, Guanquan Mao1, Bo Wei2, Shiyan Liao1, Qianqian Zhang1, Jiangchao Li1, Lingyun Zheng1, Lijing Wang3, Cuiling Qi4.   

Abstract

Breast cancer (BC) is one of the most common cancers among women in both developed and developing countries with a rising incidence. Using the MMTV-PyMT transgenic mouse model and xenografted breast cancer model, we found that R5, a neutralizing antibody to Robo1, significantly inhibited BC growth and metastasis. Angiogenesis is involved in the growth and metastasis of BC. Interestingly, R5 significantly decreases microvessel density in BC tissues, and inhibits blood vessel formation and development in in vivo chick embryo chorioallantoic membrane (CAM), yolk sac membrane (YSM) and Matrigel plug models. To investigate whether its anti-breast cancer efficacy is ascribed to its direct antiangiogenic properties, xenografted breast cancer model on CAM was established. Furthermore, R5 significantly reduces the tube formation of the vascular plexus on xenografted breast tumor on CAM. R5 also suppresses the migration and the tubular structure formation of human umbilical vein endothelial cells (HUVECs) by down-regulating the expression of filamin A (FLNA). These findings show that R5 has the potential to be a promising agent for the treatment of BC by suppressing the tumor-induced angiogenesis.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; Filamin A; Metastasis; R5; Tumor angiogenesis

Year:  2019        PMID: 31811830     DOI: 10.1016/j.yexcr.2019.111756

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  3 in total

Review 1.  Extracellular Matrix: Emerging Roles and Potential Therapeutic Targets for Breast Cancer.

Authors:  Yunchun Zhao; Xiaoling Zheng; Yongquan Zheng; Yue Chen; Weidong Fei; Fengmei Wang; Caihong Zheng
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

2.  Roundabout Guidance Receptor 1 Is an Emerging Prognostic Biomarker for Nasopharyngeal Carcinoma.

Authors:  Sung-Wei Lee; Ching-Chieh Yang; Hong-Yue Lai; Hsin-Hwa Tsai; Cheng-Fa Yeh; Yu-Hsuan Kuo; Nai-Wen Kang; Tzu-Ju Chen; Shih-Lun Chang
Journal:  Clin Med Insights Oncol       Date:  2022-07-22

Review 3.  A Comparative and Comprehensive Review of Antibody Applications in the Treatment of Lung Disease.

Authors:  Yuefeng Wu; Hai Song
Journal:  Life (Basel)       Date:  2022-01-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.